How to Choose a GLP-1 Provider as a Woman

Start with your own picture, not the ad

Most GLP-1 marketing is written as if every body is the same. Women's bodies are not, and the questions that decide whether a program is right for you are specific: Do you have PCOS or insulin resistance? Are you in the menopause transition? Do you rely on the pill for contraception, or might you want to conceive in the next year? A provider worth choosing will ask these things before it sells you anything. This guide is a checklist for finding one — it is educational only and not medical advice.

Hormonal suitability comes first

For many women, the reason GLP-1 weight will not shift is hormonal and metabolic at once. Insulin resistance sits behind much of PCOS weight and androgen excess, which is exactly the machinery these medicines act on³. A good provider treats that as central — it can talk through whether both semaglutide and tirzepatide are options, how treatment might affect your cycle, and where a GLP-1 fits alongside anything else you take. Our deeper GLP-1 and PCOS guide covers that suitability conversation in detail, and we score every program we track on exactly this — see the providers ranked for PCOS and hormonal suitability.

The four things to check

First, clinical oversight: a licensed clinician should review your history and be reachable when side effects or titration questions come up — not just at signup. "A licensed clinician" is a phrase every program uses, so the practical test is whether it will name one: one program in our ranking publishes both of its prescribing physicians' NPI numbers and all six of the pharmacies that dispense for it, which you can check yourself in the federal registry and which almost nothing else in this category offers — though it also shows the limit of the signal, because those two names are the entirety of its provider directory and neither of them works in women's health. A second program does the same thing and meets the same ceiling from a different direction: it names its four dispensing pharmacies with their phone numbers and both of its prescribing physicians with NPIs that resolve as active, and then one of those two physicians turns out to hold licenses in only two states on a desk advertising all fifty — a gap you can only see because the disclosure existed in the first place, and exactly the follow-up question to ask. That history should include real screening, not a checkbox — whether you have a current or past eating disorder and whether you have a personal history of breast cancer are both the kind of questions a genuinely careful intake asks, covered in our guides to GLP-1 and eating disorder history and GLP-1 and breast cancer history. Second, labs: ask whether baseline and follow-up bloodwork is included or expected, since that is how metabolic care is done safely; our labs and monitoring guide. He & She MD names the pharmacy that dispenses its medications in full, with a street address and a phone number lists what to ask for. A different gap is worth the same scrutiny: almost every program here reports your progress as a single weight, which cannot distinguish fat from the lean tissue GLP-1s also take off — one provider ships a body-composition analyzer with the medication and reads fat and muscle weekly, and publishes no price at all until you have finished its medical intake. Third, molecule access: programs that offer both semaglutide and tirzepatide let a clinician match the drug to you rather than to their inventory. Fourth, honest pricing: the total monthly cost, what happens at higher doses, and whether you are locked into a long prepayment — see our cost and safe-start guide. A fifth belongs beside those four, because it decides whether the other answers are even available to you: where the program is licensed to operate, and whether you can see a price before handing over an account. One operator we read in August 2026 publishes every rung of every product and never names a single state it serves; another names four dispensing pharmacies with street addresses and puts every real price behind a login.

Why oversight beats the lowest price

The cheapest sticker price usually buys the least oversight, and for women that trade-off matters more, not less — because contraception, pregnancy planning and thyroid or metabolic markers all sit in the picture⁴. The large obesity trials show what well-run treatment can do: about 15% mean weight loss with semaglutide¹ and around 20% with tirzepatide². Those results came from monitored programs, and they are the standard our Luna Fit Score methodology is built to reward. Add one more question to the four above, because it is the one that decides whether you can act on any of the others: can you leave. A seller we reviewed editorially sells its cheapest GLP-1 only as a six-month term its own product pages call non-cancelable, which turns an advertised monthly figure into an installment on a commitment you made in full at checkout. Women come off these medicines for reasons nobody can forecast at signup — a pregnancy plan, a contraception change, side effects that do not settle — and that decision should belong to you and a clinician rather than to a contract. Compare programs on oversight and hormonal fit first, then on price — and if you want the checklist already applied rather than the checklist itself, every provider we score is written up here, or filter the ranking down to the ones that meet your own conditions — tirzepatide access, brand-name availability, coverage and price. The compounded-or-brand decision sits inside the price question and is worth reading separately in our compounded versus brand-name guide.

On the question of who actually makes your medication, SnagRx names all four of its partner pharmacies with street addresses and phone numbers — a level of disclosure worth using as your benchmark when you ask anyone else.